OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PLMD59

Poly Medicure Ltd

Medical Equipment, Supplies & DistributionVerified

Poly Medicure Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.4, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after accounting for total debt, which could pose a liquidity risk. In terms of profitability, the company's return on equity (ROE) is 4.65%, and its return on assets (ROA) is 3.68%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming its peers in terms of generating returns from its equity and assets. The company's revenue is concentrated in the healthcare services and equipment segment, with no significant geographic diversification disclosed. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where demand can be sensitive to regulatory changes and economic conditions. Looking at the growth trajectory, the company's revenue has shown a positive trend, but the exact growth rate is not specified. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on capital investments. This could suggest a focus on maintaining existing operations rather than expanding. The risk assessment for Poly Medicure Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, which is a positive sign for existing shareholders. Recent events and filings do not provide specific details on the company's operations or strategic initiatives. However, the company's financial performance and risk profile suggest that it is maintaining a stable position in the market. The company's focus on healthcare services and equipment aligns with the industry's growth trends, but it needs to improve its profitability to match industry standards.

30-day price · PLMD-13.30 (-0.9%)
Low$1405.10High$1710.00Close$1439.80As of26 May, 00:00 UTC
Profile
CompanyPoly Medicure Ltd
TickerPLMD.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Poly Medicure Ltd is a medical equipment and supplies company that generates revenue primarily through the sale of healthcare products and services.

Classification. Poly Medicure Ltd is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a classification confidence of 0.92.

Poly Medicure Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.4, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after accounting for total debt, which could pose a liquidity risk. In terms of profitability, the company's return on equity (ROE) is 4.65%, and its return on assets (ROA) is 3.68%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming its peers in terms of generating returns from its equity and assets. The company's revenue is concentrated in the healthcare services and equipment segment, with no significant geographic diversification disclosed. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where demand can be sensitive to regulatory changes and economic conditions. Looking at the growth trajectory, the company's revenue has shown a positive trend, but the exact growth rate is not specified. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on capital investments. This could suggest a focus on maintaining existing operations rather than expanding. The risk assessment for Poly Medicure Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, which is a positive sign for existing shareholders. Recent events and filings do not provide specific details on the company's operations or strategic initiatives. However, the company's financial performance and risk profile suggest that it is maintaining a stable position in the market. The company's focus on healthcare services and equipment aligns with the industry's growth trends, but it needs to improve its profitability to match industry standards.
Key takeaways
  • Poly Medicure Ltd has a conservative capital structure with a low debt-to-equity ratio.
  • The company's profitability metrics are below the industry median, indicating underperformance.
  • Revenue is concentrated in the healthcare services and equipment segment.
  • The company's liquidity position is medium risk, with a negative net cash position after debt.
  • Analysts have a mixed outlook, with a mean recommendation of 2.00 (Hold).
  • The company is not expected to issue additional shares in the near term, indicating low dilution risk.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$3.78B
Gross profit$2.47B
Operating income$803.8M
Net income$683.6M
R&D
SG&A
D&A
SBC
Operating cash flow$2.66B
CapEx-$2.77B
Free cash flow
Total assets$18.59B
Total liabilities$3.89B
Total equity$14.70B
Cash & equivalents$1.35B
Long-term debt$1.74B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$7.86B$1.67B$1.36B$881.8M
FY-3$9.23B$1.59B$1.47B$208.9M
FY-2$11.15B$2.09B$1.79B-$268.4M
FY-1$13.76B$2.97B$2.58B$164.1M
FY0$16.70B$3.72B$3.39B$603.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$12.24B$9.66B
FY-3$13.77B$10.87B
FY-2$15.77B$12.42B
FY-1$18.59B$14.70B
FY0$31.92B$27.66B
PeriodOCFCapExFCFSBC
FY-4$1.19B-$951.3M$881.8M
FY-3$1.23B-$1.56B$208.9M
FY-2$1.91B-$2.39B-$268.4M
FY-1$2.66B-$2.77B$164.1M
FY0$2.40B-$3.31B$603.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$3.78B$803.8M$683.6M
FQ-6$3.85B$842.7M$740.4M
FQ-5$4.20B$944.7M$874.5M
FQ-4$4.24B$930.3M$852.3M
FQ-3$4.41B$984.3M$918.3M
FQ-2$4.03B$828.8M$930.8M
FQ-1$4.44B$897.5M$918.4M
FQ0$4.94B$756.2M$709.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$18.59B$14.70B$1.35B
FQ-6
FQ-5$30.52B$25.91B$1.79B
FQ-4
FQ-3$31.92B$27.66B$1.43B
FQ-2
FQ-1$35.87B$29.18B$1.57B
FQ0
PeriodOCFCapExFCFSBC
FQ-7$2.66B-$2.77B
FQ-6
FQ-5$653.8M-$1.53B
FQ-4
FQ-3$2.40B-$3.31B
FQ-2
FQ-1$914.4M-$1.57B
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$14.70B
Net cash-$393.5M
Current ratio2.4
Debt/Equity0.1
ROA3.7%
ROE4.7%
Cash conversion3.9%
CapEx/Revenue-73.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricPLMDActivity
Op margin21.3%3.9% medp25 -31.3% · p75 14.4%top quartile
Net margin18.1%2.4% medp25 -30.5% · p75 11.1%top quartile
Gross margin65.3%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-73.3%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity12.0%17.9% medp25 2.7% · p75 52.2%below median
Observations
IR observations
Mean price target1,697.60 INR
Median price target1,655.00 INR
High price target2,150.00 INR
Low price target1,358.00 INR
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count1.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate33.62 INR
Last actual EPS34.11 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-23 00:57 UTC#d8ffa635
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:10 UTCJob: 9ca684ec